Viewing Study NCT02971995


Ignite Creation Date: 2025-12-24 @ 1:36 PM
Ignite Modification Date: 2026-01-27 @ 3:13 AM
Study NCT ID: NCT02971995
Status: COMPLETED
Last Update Posted: 2016-11-23
First Post: 2016-11-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies
Sponsor: Lille Catholic University
Organization:

Study Overview

Official Title: Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies in Prostate Cancer Patients
Status: COMPLETED
Status Verified Date: 2015-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PROSTEPIRM
Brief Summary: Prostate cancer is the first cancer in humans (25%). The most widely used tracer in oncology, the 18-Fluoro DeoxyGlucose does not allow the study of prostatic neoplasia. On the other hand, Choline, which is an amino alcohol, is involved in the synthesis of cell membranes and has an affinity for prostate cells. Its concentration is directly proportional to cell proliferation. The analogue of choline has the advantage of having a rapid and stable accumulation over time in cancer cells, with a rapid urinary excretion (4 minutes after injection).

The goal of this study is to assess the feasibility and the accuracy for targeting image guided prostate biopsy to detect prostate cancer after Imaging fusion of choline-PET/CT compared to 1.5T multiparametric magnetic resonance imaging (mpMRI) with 3D-transrectal ultrasound (TRUS) .
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: